Clinical Trial Update: Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT) [Phase 3]

View source ↗

Summary

A Phase 3 trial of sofosbuvir/ledipasvir in liver transplant recipients to prevent hepatitis C recurrence was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir (ledipasvir)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hepatitis C Viral Infection | Phase 3 | Status: TERMINATED